

Curriculum Vitae

Professional address

Oncology Institute of Southern Switzerland
Ospedale San Giovanni
Via A Gallino 12, 6500 Bellinzona, Switzerland

Clinical Trial Unit Ente Ospedaliero Cantonale - CTU-EOC
Area Formazione medica e Ricerca - AFRi
c/o Università della Svizzera italiana
Via Buffi 13, 1° Piano LAB, 6900 Lugano, Switzerland

Phone: 0041-91-811-8931

e-mail: anastasios.stathis@eoc.ch

Present employment and academic role

Since Sep 2024	Head of Research Service and Scientific Director Clinical Trial Unit, Ente Ospedaliero Cantonale, Lugano, Switzerland
Since Sep 2024	Phase I Program Lead, Oncology Institute of Southern Switzerland, Ente Ospedaliero Cantonale, Bellinzona, Switzerland
Since Apr 2023	Adjunct Professor, USI-Università della Svizzera Italiana, Faculty of Biomedical Sciences, Lugano, Switzerland
Since Jun 2017	Senior attending physician, Oncology/Hematology Oncology Institute of Southern Switzerland, EOC-Ente Ospedaliero Cantonale, Bellinzona, Switzerland

Working Experience

Jan 2018 - Aug 2024	Head of New Drugs Development Unit and Chair of Clinical Research, Oncology Institute of Southern Switzerland, Ente Ospedaliero Cantonale, Ospedale San Giovanni, Bellinzona, Switzerland
---------------------	---

- Feb 2011 - May 2017 Attending Physician, Phase I solid tumors and lymphoma outpatient clinics, Oncology Institute of Southern Switzerland, Ente Ospedaliero Cantonale, Ospedale San Giovanni, Bellinzona, Switzerland
- Aug 2010 - Jan 2011 Attending Physician, Inpatient Medical Oncology, Oncology Institute of Southern Switzerland, Ente Ospedaliero Cantonale, Ospedale San Giovanni, Bellinzona, Switzerland
- Jun 2008 - Jun 2010 Clinical research fellow, Drug Development Program, Medical Oncology and Hematology, Princess Margaret Hospital, Toronto, Canada
- Dic 2007 - Jun 2008 Clinical research fellow, Clinical Research Unit, Oncology Institute of Southern Switzerland, Ospedale San Giovanni, Bellinzona, Switzerland
- Nov 2006 - Nov 2007 Resident Medical Oncology, Department of Oncology, Ospedale di Circolo & Fondazione Macchi, Varese, Italy
- Nov 2005 - Oct 2006 Resident Medical Oncology, Oncology Institute of Southern Switzerland, Ospedale San Giovanni, Bellinzona, Switzerland
- Sep 2003 - Oct 2005 Resident Medical Oncology, Department of Oncology, Ospedale di Circolo & Fondazione Macchi, Varese, Italy

Degrees/Certificates

- | | |
|------|--|
| 2016 | Certificate of Competence in lymphomas. European School of Oncology (ESO) and Ulm University |
| 2015 | Swiss Recognition (FMH) of Medical Oncology Specialty |
| 2013 | European Certificate of Medical Oncology. European School of Medical Oncology (ESMO) exam |
| 2007 | Specialty Degree in Oncology. University of Insubria, Varese (Italy) |
| 2003 | M.D. University of Pavia (Italy) |

Post-graduate Training

- | | |
|-------------|--|
| June 2014 | Visiting Physician, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, USA |
| 2008 - 2010 | Clinical Research Fellow, Drug Development Program, Princess Margaret Hospital, Faculty of Medicine, University of Toronto, Canada |

2007 - 2008 Clinical Research Fellow, Clinical Research Unit, Oncology Institute of Southern Switzerland, Bellinzona, Switzerland

2003 - 2007 Resident, Medical Oncology, University of Insubria, Varese, Italy and Oncology Institute of Southern Switzerland, Bellinzona, Switzerland

Other scientific roles and leadership appointments

Since 2024 Editor for Cancer Treatment Reviews

Since 2023 Scientific Co-chair ESMO Targeted Anticancer Therapeutics (TAT) Annual Meeting

Since 2022 President, Project Group Developmental Therapeutics, Swiss Group for Clinical Cancer Research (SAKK)

Since 2021 Member of the pharmacology and molecular mechanisms group of EORTC

Since 2021 Member of the scientific committee of the ESMO targeted anticancer therapeutics (TAT)

Since 2019 Organizer of the “Teaching Conferences” of the Oncology Institute of Southern Switzerland

Since 2017 Member of the local Organizing Committee International Conference on Malignant Lymphoma (ICML)

Since 2017 Reviewer abstracts International Conference on Malignant Lymphoma (ICML)

2024 Member of the Developmental Therapeutics Track of the ESMO 2024 Meeting

2021-2024 Member of the evaluation committee of research proposals for the French National Cancer Institute

2016-2023 Editor for Critical Reviews in Oncology Hematology

2022 Member of ESMO Asia 2022 Scientific committee, developmental and precision medicine track

2021 Member of the developmental therapeutics track session of the ESMO 2021 meeting

2020 Reviewer abstracts American Society of Hematology (ASH) annual meeting

Awards

2023 Prize and Recognition for Merit for the Year 2023, City of S. Antonino, Switzerland

2023 Included in the list of the world's "2% top-cited researchers" published by the University of Stanford and Elsevier

2017 Pfizer Research Award in Oncology

2014 ABREOC award: Best oral presentation at the 4th Clinical Research Day of the Italian Switzerland

2009 American Society of Clinical Oncology (ASCO) Merit Award

2009 Novartis Oncology Young Canadian Investigator Award (NOYCIA)

Licensure

2010 Health Department, Canton Ticino, Switzerland

2008 College of Physicians & Surgeons of Ontario, Canada

2003 College of Physicians of Varese, Italy

Professional memberships

Since 2018 American Association for Cancer Research (AACR)

Since 2014 College of physicians, Canton Ticino, Switzerland

Since 2012 Swiss Medical Association (FMH)

Since 2011	Swiss Group for Clinical Cancer Research (SAKK), Developmental Therapeutics Group and Lymphoma Group
Since 2008	American Society of Clinical Oncology (ASCO)
Since 2007	European Society of Medical Oncology (ESMO)

Teaching experience and prior academic positions

Since 2020	Faculty of Biomedical Sciences Università della Svizzera Italiana, Lugano, Switzerland
Since 2018	Experimental Pharmacology, residents in medical oncology, Oncology Institute of Southern Switzerland
Since 2017	Clinical case presentations at the medical students (“candmed”) of the Ospedale San Giovanni
Since 2013	Certificate of competence in Lymphoma, ESO and ULM University
Since 2011	Specialization School in Oncology, University of Insubria, Varese Italy
Since 2011	Bachelor in Nursing care and advanced studies in oncology, Department of Business Economics, Health and Social Care, SUPSI
2018-2023	Privatdozent-PD, USI-Università della Svizzera Italiana, Faculty of Biomedical Sciences, Lugano, Switzerland
2022-2023	Contract Professor, University of Padua, Italy, Specialization school in medical oncology
2022-2023	Docent: Specialization school of oncology, University of Padua, Italy
2020-2023	Docent: Bachelorstudium Humanmedizin an der ETH Zürich/Onkologie, Switzerland

Direction of thesis

2024	Master thesis, Faculty of Biomedical Sciences, Lugano, Switzerland, Student: Pero Antic, Title: KRAS mutation in non-small-cell lung carcinoma: baseline characteristics and treatment outcome
------	--

2024	Master thesis, Faculty of Biomedical Sciences, Lugano, Switzerland, Student: Kevin Huynh, Title: Baseline features and outcome of patients with relapsed/refractory diffuse large B-cell lymphoma
2023	Specialization thesis in Oncology, Scuola di Specializzazione in Oncologia Medica, University of Padua, Italy, Dr Marini Sabrina, Title: Outcome and Prognostic Factors in Patients with Non-Small Cell Lung Cancer and Brain Metastases: A Retrospective Analysis
2023	Master thesis, Faculty of Biomedical Sciences, Lugano, Switzerland, Student: Nina Alissa Schätti, Title: Baseline characteristics and outcome of patients with gynecological malignancies enrolled in phase I clinical trials: A single-center experience.
2023	Specialization thesis in Oncology, Scuola di Specializzazione in Oncologia Medica, University of Padua, Italy, Dr Pretelli Giulia, Title: Baseline characteristics and outcome of cancer patients enrolled in phase I clinical trials.
2022	MD thesis, Faculty of Biomedical Sciences, Lugano, Switzerland, Dr Maria Francesca Zorzi, Title: A systematic review of contemporary phase I trials in patients with lymphoma.
2021	Specialization thesis in Oncology, Dipartimento di Medicina Traslazionale e per la Romagna. Scuola di Specializzazione in Oncologia Medica, Dr Zielli Teresa, Title: Baseline inflammatory status and metabolic tumor burden on FDG PET/CT scans predicts outcome in metastatic NSCLC patients treated with immune checkpoint inhibitors in first line.
2019	Specialization thesis in Oncology, Istituto di Candiolo - Fondazione del Piemonte per l'Oncologia Dr Sofia Genta, Title: Clear cell ovarian carcinoma: new therapeutic opportunities from early phase studies.

GCP training and other professional or academic courses

11/2022:	GCP refresher, Clinical trial Unit-Ente Ospedaliero Cantonale;
12/2020:	Teaching in the classroom, Università della Svizzera Italiana
12/2020:	Teaching in the clinic, Università della Svizzera Italiana
05/2020:	GCP (GCP-E6(R2) 2016); Swiss National Supplement, Informed Consent, Research Ethics Evaluation, Introduction to Research Ethics

01/2019: Teach the teacher, Università della Svizzera Italiana

10/2017: Intra and interpersonal abilities course Ente Ospedaliero Cantonale

10/2017 GCP for investigators First Level, Clinical Trial Unit, EOC

02/2017: Effective People course, Ente Ospedaliero Cantonale

01/2017: Gordon communication course, Ente Ospedaliero Cantonale

03/2016: LEO course, Ente Ospedaliero Cantonale

01/2014: GCP for investigators and sponsors, Clinical Trial Unit, EOC, Module 3

10/2012: Swiss Group for Clinical Cancer Research (SAKK) Investigator's Education

Principal investigator in oncology clinical trials

A Study of AMG 355 Alone and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors. NCT06131398

A Phase I Study of BMS986458 Alone and in Combination with Anti-Lymphoma Agents in Relapsed/Refractory NHL. NCT06090539

A Phase 1 Open-Label, Multi-Center, Safety and Efficacy Study of PRT2527 as Monotherapy and in Combination with Zanubrutinib in Participants with Relapsed/Refractory Hematologic Malignancies. NCT05665530

A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors NCT05836324

A Phase 3, Open-Label Study to Evaluate Safety and Efficacy of Epcoritamab in Combination With Rituximab and Lenalidomide (R2) Compared to R2 in Subjects With Relapsed or Refractory Follicular Lymphoma (EPCORE FL-1). NCT05409066

A Phase 1, Open-label, Multicenter Study to Assess Safety, Tolerability, PK, and Efficacy of MK-6598 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors. NCT05594043

A Phase 3, Randomized, Open-Label Study Evaluating the Efficacy of Axicabtagene Ciloleuceel versus Standard of Care Therapy in Subjects with Relapsed/Refractory Diffuse Large B Cell Lymphoma (ZUMA-7). NCT03391466

A Phase III Open-Label, Randomized Study of LOXO-305 versus Investigator Choice of BTK Inhibitor in Patients with Previously Treated BTK Inhibitor Naïve Mantle Cell Lymphoma (BRUIN MCL-321). NCT04662255

Assessing a ctDNA and PET-oriented therapy in patients with DLBCL. A multicenter, open-label, phase II trial. NCT04604067.

Phase II trial of acalabrutinib in combination with tafasitamab in patients with previously treated marginal zone lymphomas (MZL). NCT04646395

A Phase I, Open-Label, Multicenter Study to Assess Safety, Tolerability, PK, and Efficacy of MK-1084 as Monotherapy and in Combination With Pembrolizumab in Subjects with KRASG12C Mutant Advanced Solid Tumors. NCT05067283

A Phase I/Phase II Study to Evaluate the Safety and Tolerability of MK-1088 as Monotherapy and in Combination with Pembrolizumab in Participants with Advanced Solid Tumors. NCT05394350

A Phase I, dose-finding study of Debio 0123 as monotherapy in adult patients with advanced solid tumors, followed by an expansion part to assess safety and preliminary anti-tumor activity. NCT05109975

A phase I/Ib/II study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of AMG 193 alone and in combination with docetaxel in subjects with advanced MTAP-null solid tumors. NCT05094336

Tumor-Agnostic Precision Immuno-Oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study. NCT04589845

Protocol 402-311: A Phase 3 Randomized Study of Loncastuximab Tesirine Combined with Rituximab Versus Immunochemotherapy in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) (LOTIS-5). NCT04384484

Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) in Previously Treated Participants With Select Solid Tumors (MK-7902-005/E7080-G000-224/LEAP-005). NCT03797326

SAKK 80/19. Alpine Tumor Immunology Registry

SAKK 80/20. Outcome and prognostic factors of SARS-CoV-2 infection in cancer patients: A cross sectional study

A phase I study to evaluate safety and early signs of efficacy of the human monoclonal antibody-cytokine fusion protein IL12-L19L19. NCT04471987

A Phase 1/2 Study of Oral LOXO-305 in Patients with Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) or Non-Hodgkin Lymphoma (NHL). NCT03740529

SAKK 66/18: Copanlisib in combination with venetoclax in patients with relapsed or refractory B-cell non-Hodgkin lymphoma. A multicenter phase Ib trial with two expansion cohorts. NCT0388664in9

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Two-Arm, Phase 2 Study of ME-401 in Subjects with Follicular Lymphoma After Failure of Two or More Prior Systemic Therapies. NCT03768505

Phase 1b Open-label Study of MK-8353 in Combination with Selumetinib (MK-5618) in Participants with Advanced/Metastatic Solid Tumors. NCT03745989

Protocol SAKK 65/16 TLD-1, a novel Liposomal Doxorubicin, in Patients with Advanced Solid Tumors; a multicenter open-label single arm phase I trial. NCT03387917

Protocol SAKK 57/16 NAPAGE: NAb-PAclitaxel and GEmcitabine in advanced soft tissue sarcoma. A multicenter open-label single arm phase Ib/IIa trial. NCT03524898

A Phase 1 Study of LY3200882 in Patients with Solid Tumors. NCT02937272

A Phase 2 Open-Label Single-Arm Study to Evaluate the Efficacy and Safety of Loncastuximab Tesirine in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL). NCT03589469

An open-label, first-in-human, dose-escalation study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and maximum tolerated dose and/or recommended Phase II dose of the ATR inhibitor BAY 1895344 in patients with advanced solid tumors and lymphomas. NCT03188965

A phase II study exploring the safety and efficacy of atezolizumab administered in combination with obinutuzumab or rituximab anti-CD20 therapy in patients with relapsed/refractory mantle cell lymphoma, marginal zone lymphoma and waldenström macroglobulinemia. EUDRACT 2016-003579-22

A Phase 2 Open-Label Study to Determine the Effect of Blinatumomab on Minimal Residual Disease in Subjects With High-risk Diffuse Large B-cell Lymphoma Post-autologous Hematopoietic Stem-cell Transplantation. NCT03298412

A Phase III, randomized, double-blind, controlled, multicenter study of intravenous PI3K inhibitor copanlisib in combination with standard immunochemotherapy versus standard immunochemotherapy in patients with relapsed indolent non-Hodgkin's lymphoma (iNHL) - CHRONOS-4. NCT02626455

A Phase 1b, Open-Label, Dose Escalation Study of ME-401 in Subjects with Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) or Follicular Lymphoma. NCT02914938

A phase I/IIa, multi-centre, open-label, dose-escalation study with expansion arms to assess the safety, tolerability, pharmacokinetics and preliminary efficacy of CB-103 administered orally in adult patients with advanced or metastatic solid tumours and haematological malignancies characterised by alterations of the notch signalling pathway. NCT03422679

A phase I dose finding study of oral LTT462 in adult patients with advanced solid tumors harboring MAPK pathway alterations. NCT02711345

An open-label Phase 1/2a study of BAL101553 administered as intravenous 48-hour infusions in adult patients with advanced solid tumors or recurrent glioblastoma. NCT02895360

CPDR00IX2106- Phase I/Ib, multi-center, open-label study of single agent CJM112, and PDR001 in combination with LCL161 or CJM112 in patients with relapsed and/or refractory multiple myeloma. NCT03111992

SAKK 35/15. A phase I trial of obinutuzumab in combination with venetoclax in previously untreated follicular lymphoma patients. NCT02877550

Phase 3 Randomized, Double-Blind, Placebo Controlled, Multicenter Study To Compare The Efficacy And Safety Of Lenalidomide (CC-5013) Plus R-CHOP Chemotherapy (R2-CHOP) Versus Placebo Plus R-CHOP Chemotherapy In Subjects With Previously Untreated Activated B-Cell Type Diffuse Large B-Cell Lymphoma. NCT02285062

A Phase 2 Study to Evaluate the Efficacy and Tolerability of Debio 1562 in Combination with Rituximab in Patients with Relapsed and/or Refractory Diffuse Large B-Cell Lymphoma and Other Forms of Non-Hodgkin's Lymphoma. NCT02564744

A Phase IB Dose Exploration Trial with MK-8628, a Small Molecule Inhibitor of the Bromodomain and Extra-Terminal (BET) Proteins, in Subjects with Selected Advanced Solid Tumors. NCT02698176

A Phase IB Trial with MK-8628, a Small Molecule Inhibitor of the Bromodomain and Extra-Terminal (BET) Proteins, in Subjects with Selected Hematologic Malignancies. NCT02698189

Phase I study of oral PQR309 in Patients with Relapsed or Refractory Lymphomas. NCT02249429

Phase I multicenter, open-label, clinical and pharmacokinetic study of lurbinectedin (PM01183) in combination with cisplatin in patients with advanced solid tumors. NCT01980667

Dose finding study of PF-05212384 with paclitaxel and carboplatin in patients with advanced solid tumors. NCT02069158

A Phase IB Trial with OTX015, a Small Molecule Inhibitor of the Bromodomain and Extra-Terminal (BET) Proteins, in Patients with Selected Advanced Solid Tumors. NCT02259114

A phase I, dose-finding study of the bromodomain (Brd) inhibitor OTX015 in haematological malignancies. NCT01713582

A phase II study of Chlorambucil in combination with subcutaneous Rituximab followed by maintenance therapy with subcutaneous Rituximab in patients with extranodal marginal zone B-cell lymphoma of mucosa associated lymphoid tissue (MALT lymphoma). NCT01808599

SAKK 65/12. LDE225 in combination with Paclitaxel in patients with advanced solid tumors. A multicenter phase I trial. NCT01954355

A Phase I, Multi-center, Open-label Study of IMG529 Administered Intravenously in Adult Patients with Relapsed or Refractory Non-Hodgkin's Lymphoma. NCT01534715

A Phase I study of Inotuzumab Ozogamicin (CMC-544) in combination with Temsirolimus (CCI-779) in patients with relapsed or refractory CD22-positive B-cell Non Hodgkin's Lymphomas. NCT01535989

Grants and development of investigator initiated clinical trials

Grants

Funding of senior clinical or laboratory researchers active in EOC - 2023 CHF 60.000 (Main applicant)

Funding of junior clinical or laboratory researchers active in EOC - 2022 CHF 50'000, Dr Ilaria Colombo (Supervisor)

Swiss Cancer Research (2019-2022). KFS-4727-02-2019. CHF 370440. An integrated approach to identify the mechanism of resistance to copanlisib and venetoclax in marginal zone lymphoma (Co-applicant)

Finding a way to by-pass the resistance to PI3K inhibitors in marginal zone lymphomas. Fondazione Ticinese per la Ricerca sul Cancro. 06-2019: 05-2020. CHF 60,000. (Co-applicant)

Grant ABREOC Dr Ilaria Colombo (2019), CHF 55000: Molecular Characterization of Solid Tumors and Lymphomas to Optimize the Drug Development Process and Patients Enrollment in Early Phase Clinical Trials (Supervisor)

San Salvatore Foundation (2016-2018). CHF 70600. Novel Active Combinations Containing Bromodomain (BRD) and Extra-terminal (BET) Inhibitors for Patients with Germinal Center B-cell Type Diffuse large B-cell lymphoma. (Co-applicant)

Development of Investigator initiated clinical trials

IELSG 49. Phase II trial of acalabrutinib in combination with tafasitamab in patients with previously treated marginal zone lymphomas (MZL). NCT04646395. Study ongoing ([Study chair](#))

Protocol SAKK 38/19: Assessing a ctDNA and PET-oriented therapy in patients with DLBCL. A multicenter, open-label, phase II trial. NCT04604067. Study ongoing. ([Study chair](#))

SAKK 66/18. Copanlisib in combination with venetoclax in patients with relapsed or refractory B-cell non-Hodgkin lymphoma. A multicenter phase Ib trial with two expansion cohorts. NCT03886649. Study completed ([Study chair](#))

SAKK35/15. A phase I study of obinutuzumab in combination with venetoclax in previously untreated patients with follicular lymphoma. NCT02877550. Study completed. ([Study chair](#))

A phase II study of Chlorambucil in combination with subcutaneous Rituximab followed by maintenance therapy with subcutaneous Rituximab in patients with extranodal marginal zone B-cell lymphoma of mucosa associated lymphoid tissue (MALT lymphoma). NCT01808599. Study completed. ([Study chair](#))

LDE225 in combination with Paclitaxel in patients with advanced solid tumors. A multicenter phase I trial. NCT01954355. Study completed. ([Study chair](#))

A Phase I study of Inotuzumab Ozogamicin (CMC-544) in combination with Temsirolimus (CCI-779) in patients with relapsed or refractory CD22-positive B-cell Non Hodgkin's Lymphomas. NCT01535989. Study completed ([Study chair](#))

A phase I study of the oral gamma secretase inhibitor R04929097 in combination with Gemcitabine in patients with advanced solid tumors. PMH, Toronto, Canada. Study completed. NCT01145456. Study completed. ([Study fellow](#))

Invited presentations - major international meetings

ESMO 2024:	Highlights Developmental Therapeutics
ESMO 2023:	Management of novel treatments' toxicities: Toxicities of TILs, CAR-Ts and bispecific antibodies.
ESMO Asia 2022:	A peek into the future of precision medicine. Targeting KRAS,
ESMO 2021:	Controversy session: "Targeting molecular residual disease in solid tumours will increase cure rates?: NO",

ICML 2021:	Meet the professor: “New drugs and pharmacological interactions in real life”,
ESMO TAT 2021:	Educational session: “Molecular profiling for target-based studies”,
ESMO 2020:	Discussant in mini-oral Developmental Therapeutics session
ESMO 2019:	Discussant and chair in proffered paper session haematologic malignancies
ASCO 2018:	Discussant in poster discussion session: Inhibition of Transcriptional and Epigenetics Targets

First or last author presentations/posters- major international meetings

ICML 2023:	A. Stathis , F. Hitz , S. Schär , U. Novak , N. Fischer , U. Mey , G. Gritti, T. Zander, N. Lang, A. Cairoli, T. Zenz, G. Rhyner, W. Mingrone, A. Schmidt, G. Gaidano, S. Hohaus, A. O. Stern, C. Mamot , A. Bruscajin, J. Musilova, S. Hayoz, F. Bertoni, E. Zucca, S. Dirnhofer, L. Ceriani, D. Rossi, SAKK 38/19: Assessing a ctDNA and PET-oriented therapy in patients with DLBCL. A multicenter, open-label, phase II trial. ORAL PRESENTATION.
ESMO 2020:	M. Joerger, Y. Metaxas, A. Schmitt, D. Koeberle, K. Zaman, D. Betticher, N. Mach, C. Renner, M.T. Mark, U. Petrausch, C.B. Caspar, C. Britschgi, C. Taverna, F. Zenger, W. Mingrone, J. Schulz, C. Kopp, S. Hayoz, A. Stathis* , R. von Moos*. Outcome and prognostic factors of SARS CoV-2 infection in cancer patients: A cross-sectional study (SAKK 80/20 CaSA). Mini ORAL PRESENTATION (* co-senior authors)
ESMO 2020:	A.B. Azaro Pedrazzoli, J.M. Perez Garcia, J. Cortés, E. Lopez Miranda, I. Colombo, E. Garralda, D. Hess, P.G. Nuciforo, A. Vivancos, R. Ferrarotto, O. Schoenborn-Kellenberger, K. Jorga, M. Vigolo, L. Beni, R. Lehal, M. Murone, M. Bauer, P. Pisa, F.D. Vogl, A. Stathis . Target engagement and clinical safety of CB-103, a first-in-class small molecule inhibitor of the NOTCH transcription complex. POSTER
ESMO 2020:	Colombo, S. Genta, F. Martorana, M. Guidi, P. Samartzis, S. Brandt, S. Gaggetta, L. Moser, M.R. Pascale, T. Terrot, C. Sessa, A. Stathis . Phase I dose-escalation study of the dual PI3K/mTORC1/2 inhibitor Gedatolisib (PF-05212384) in combination with paclitaxel (P) and carboplatin (C) in patients (pts) with advanced solid tumours. POSTER

- ICML 2019: **A Stathis**, U. Mey, S. Schär, F. Hitz, C. Pott, N. Mach, F. Krasniqi, U. Novak, C. Schmidt, K. Hohloch, D. Kienle, D. Hess, A. Moccia, M. Unterhalt, K. Eckhardt, S. Hayoz, D. Rossi, S. Dirnhofer, L. Ceriani, F. Bertoni, C. Buske, E. Zucca, W. Hiddemann. SAKK35/15, A phase I study of obinutuzumab in combination with venetoclax in previously untreated patients with follicular lymphoma. ORAL PRESENTATION
- ASH 2017: **A Stathis**, A Gregorini, R Gressin, L Orsucci, A Perrot, M Tani, B Coiffier, G Musuraca, R Guieze, D Marino, G Gini, A Ferrari, E Gyan, F Morschhauser, F Palombi, F Cavallo, S Le Gouill, H Tilly, F Salvi, A Conconi, MG Cabras, E Capochiani, C Califano, AL Molinari, A Pulsoni, N Ielmini, S Luminari, F Cavalli, E Zucca, and C Thieblemont. IELSG-38: A Phase II Study of Chlorambucil in Combination with Rituximab Followed By Maintenance Therapy with Subcutaneous Rituximab in Patients with Extranodal Marginal Zone B-Cell Lymphoma of Mucosa Associated Lymphoid Tissue (MALT). POSTER
- ICML 2015: **A Stathis**, A. Vanazzi, M. Negri, D. Laszlo, A. Conconi, K. Aprile von Hohenstaufen, A. A. Moccia, M. Miani, F. Cavalli, G. Martinelli, E. Zucca. Phase II study for the evaluation of feasibility, activity and safety of Bendamustine and Ofatumumab in combination in marginal zone B-cell lymphomas (MZL). POSTER
- ASH 2014: **A Stathis**, A S. Freedman, I W. Flinn, K J. Maddocks, S Weitman, J G. Berdeja, A V. Mejia, E Zucca, R Green, A Romanelli, S H Zildjian, R Ruiz-Soto, L Palomba A Phase I Study of IMG529, an Antibody-Drug Conjugate (ADC) Targeting CD37, in Adult Patients with Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (NHL). POSTER
- EORTC-NCI-AACR 2014: **A Stathis**, B. Quesnel, S. Amorim, C. Thieblemont, E. Zucca, E. Raffoux, H. Dombert, Y. Peng, A. Palumbo, N. Very, X. Thomas, M. Michallet, C. Gomez-Roca, C. Recher, L. Karlin, K. Yee, K. Rezai, C. Pseudhomme, T. Facon, P. Herait. Results of a first-in-man trial assessing OTX015, an orally available BET-bromodomain (BRD) inhibitor, in advanced hematologic malignancies. symposium. ORAL-PLENARY SESSION
- ASCO 2014: **A Stathis**, K J. Maddocks, I Flinn, A Mejia, M Palomba, S Zildjian, M Murphy, J Deckert, R Ruiz-Soto, A Freedman. Preliminary findings from a phase I, multicenter, open-label study of the anti-CD37 antibody-drug

conjugate (ADC), IMGN529, in adult patients with relapsed or refractory non-Hodgkin lymphoma (NHL). POSTER DISCUSSION

AACR 2014: **A Stathis**, F. Hitz, U. Novak, F. Bertoni, T. Terrot, L. Moser, I. Xenidou, L. Mazzucchelli, M. Ghielmini, C. Sessa, E. Zucca, F. Cavalli. A phase I study of inotuzumab ozogamicin in combination with temsirolimus in patients with relapsed or refractory CD22-positive B-cell non-Hodgkin lymphomas (NHL). POSTER

ASCO 2010: **A Stathis**, D. J. Renouf and M. J. Moore. Phase II trials (P2T) in advanced pancreatic cancer (APC): Systematic review with focus on the design, entry criteria, and endpoints used. POSTER

ASCO 2009: **A Stathis**, S. Hotte, H. Hirte, E. X. Chen, S. Webster, A. Iacobucci, S. McGill, L. Wang, I. Espinoza-Delgado and L. L. Siu. Phase I study of intravenous decitabine in combination with oral vorinostat in patients with advanced solid tumors and non-Hodgkin's lymphomas (NHL). POSTER DISCUSSION

LIST OF PUBLICATIONS

ORIGINAL PAPERS IN PEER-REVIEWED JOURNALS

1. Are bone targeted agents still useful in times of immunotherapy? The SAKK 80/19 BTA pilot study. Mark M, Mora AR, Winder T, **Stathis A**, Jakob A, Müller G, Hayoz S, Reimann P, Petrausch U, von Moos R; Swiss Group for Clinical Cancer Research (SAKK). *Bone Rep.* 2024 Jul 23;22:101794. doi: 10.1016/j.bonr.2024.101794. PMID: 39139592; PMCID: PMC11321436.
2. Targeting CD25+ lymphoma cells with the antibody-drug conjugate camidanlumab tesirine as a single agent or in combination with targeted agents. Spriano F, Tarantelli C, Cascione L, Gaudio E, Golino G, Scalise L, Cacciapuoti MT, Zucca E, **Stathis A**, Van Berkel PH, Inghirami G, Zammarchi F, Bertoni F. *Br J Haematol.* 2024 Jul 30. doi: 10.1111/bjh.19658. Epub ahead of print. PMID: 39080847.
3. A first-in-class Wiskott-Aldrich syndrome protein activator with anti-tumor activity in hematologic cancers. Spriano F, Sartori G, Sgrignani J, Barnabei L, Arribas AJ, Guala M, Del Amor AMC, Tomasso MR, Tarantelli C, Cascione L, Golino G, Riveiro ME, Bortolozzi R, Lupia A, Paduano F, Huguet S, Rezai K, Rinaldi A, Margheriti F, Ventura P, Guarda G, Costa G, Rocca R, Furlan A, Verdonk LM, Innocenti P, Martin NI, Viola G, Driessen C, Zucca E, **Stathis A**, Gahtory D, Van den Nieuwboer M, Bornhauser B, Alcaro S, Trapasso F, Cristobal S, Padrick SB, Pazzi N, Cavalli F, Cavalli A, Gaudio E, Bertoni F. *Haematologica.* 2024 Jun 20. doi: 10.3324/haematol.2022.282672. Epub ahead of print. PMID: 38899342.
4. Population pharmacokinetics of TLD-1, a novel liposomal doxorubicin, in a phase I trial. Mc Laughlin AM, Hess D, Michelet R, Colombo I, Haefliger S, Bastian S, Rabaglio M, Schwitter M, Fischer S, Eckhardt K, Hayoz S, Kopp C, Klose M, Sessa C, **Stathis A**, Halbherr S, Huisinga W, Joerger M, Kloft C. *Cancer Chemother Pharmacol.* 2024 Jun 15. doi: 10.1007/s00280-024-04679-z. Epub ahead of print. PMID: 38878207.
5. Targeting CD19-positive lymphomas with the antibody-drug conjugate loncastuximab tesirine: preclinical evidence as single agent and in combination therapy. Tarantelli C, Wald D, Munz N, Spriano F, Brusca A, Cannas E, Cascione L, Gaudio E, Arribas AJ, Manjappa S, Golino G, Scalise L, Cacciapuoti MT, Zucca E, **Stathis A**, Inghirami G, Van Berkel PH, Rossi D, Caimi PF, Zammarchi F, Bertoni F. *Haematologica.* 2024 May 9. doi: 10.3324/haematol.2023.284197. Epub ahead of print. PMID: 38721745.

6. IELSG38: phase II trial of front-line chlorambucil plus subcutaneous rituximab induction and maintenance in mucosa-associated lymphoid tissue lymphoma. **Stathis A**, Pirosa MC, Orsucci L, Feugier P, Tani M, Ghesquières H, Musuraca G, Rossi FG, Merli F, Guièze R, Gyan E, Gini G, Marino D, Gressin R, Morschhauser F, Cavallo F, Palombi F, Conconi A, Tessoulin B, Tilly H, Zanni M, Cabras MG, Capochiani E, Califano C, Celli M, Pulsoni A, Angrilli F, Occhini U, Casasnovas RO, Cartron G, Devizzi L, Haioun C, Liberati AM, Houot R, Merli M, Pietrantuono G, Re F, Spina M, Landi F, Cavalli F, Bertoni F, Rossi D, Ielmini N, Borgo E, Luminari S, Zucca E, Thieblemont C. *Haematologica*. 2024 Feb 22. doi: 10.3324/haematol.2023.283918. Epub ahead of print. PMID: 38385243.

7. TLD-1, a novel liposomal doxorubicin, in patients with advanced solid tumors: Dose escalation and expansion part of a multicenter open-label phase I trial (SAKK 65/16). Colombo I, Koster KL, Holer L, Haefliger S, Rabaglio M, Bastian S, Schwitter M, Eckhardt K, Hayoz S, Mc Laughlin AM, Kloft C, Klose M, Halbherr S, Baumgartner C, Sessa C, **Stathis A**, ¶ Hess D¶, Joerger M. ¶ ¶ **Equally contributed** *Eur J Cancer*. 2024 Apr;201:113588. doi: 10.1016/j.ejca.2024.113588. Epub 2024 Feb 2. PMID: 38377773.

8. Clinical outcomes of older and younger patients treated with loncastuximab tesirine in the LOTIS-2 clinical trial. Hamadani M, Spira A, Zhou X, Liao L, Chen L, Radford J, Ai W, Solh M, Ardesna KM, Hess B, Caimi PF, **Stathis A**, Carlo-Stella C, Alderuccio JP, Kahl B, Wang Y, Qin Y, Xu ZC, Zinzani PL. *Blood Adv*. 2024 Jan 9;8(1):93-98. doi: 10.1182/bloodadvances.2023010636. PMID: 37871303; PMCID: PMC10787240.

9. PET/CT Biomarkers Enable Risk Stratification of Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma Enrolled in the LOTIS-2 Clinical Trial Alderuccio JP, Reis IM, Hamadani M, Nachiappan M, Leslom S, Kahl BS, Ai WZ, Radford J, Solh M, Ardesna KM, Hess BT, Lunning MA, Zinzani PL, **Stathis A**, Carlo-Stella C, Lossos IS, Caimi PF, Han S, Yang F, Kuker RA, Moskowitz CH. *Clin Cancer Res*. 2024 Jan 5;30(1):139-149. doi: 10.1158/1078-0432.CCR-23-1561. PMID: 37855688.

10. IELSG30 phase 2 trial: intravenous and intrathecal CNS prophylaxis in primary testicular diffuse large B-cell lymphoma. Conconi A, Chiappella A, Ferreri AJ, **Stathis A**, Botto B, Sassone M, Gaidano G, Balzarotti M MD, Merli F, Tucci A, Vanazzi A, Tani M, Bruna R, Orsucci L, Cabras MG, Celli M, Annibali O, Liberati AM, Zanni M, Ghiggi C, Pisani F, Pinotti G, Dore F, Esposito F, Pirosa MC, Cesaretti M, Bonomini L, Vitolo U, Zucca E. *Blood Adv*. 2024 Jan 4;bloodadvances.2023011251. doi: 10.1182/bloodadvances.2023011251. Epub ahead of print. PMID: 38181782.

11. The ATR inhibitor elimusertib exhibits anti-lymphoma activity and synergizes with the PI3K inhibitor copanlisib. Sartori G, Tarantelli C, Spriano F, Gaudio E, Cascione L,

Mascia M, Barreca M, Arribas AJ, Licenziato L, Golino G, Ferragamo A, Pileri S, Damia G, Zucca E, **Stathis A**, Politz O, Wengner AM, Bertoni F.
Br J Haematol. 2024 Jan;204(1):191-205. doi: 10.1111/bjh.19218. Epub 2023 Nov 27. PMID: 38011941.

12. ERBB4-Mediated Signaling Is a Mediator of Resistance to PI3K and BTK Inhibitors in B-cell Lymphoid Neoplasms. Arribas AJ, Napoli S, Cascione L, Barnabei L, Sartori G, Cannas E, Gaudio E, Tarantelli C, Mensah AA, Spriano F, Zucchetto A, Rossi FM, Rinaldi A, Castro de Moura M, Jovic S, Bordone Pittau R, **Stathis A**, Stussi G, Gattei V, Brown JR, Esteller M, Zucca E, Rossi D, Bertoni F.
Mol Cancer Ther. 2023 Dec 5:OF1-OF13. doi: 10.1158/1535-7163.MCT-23-0068. Epub ahead of print. PMID: 38052765.
13. Targeting myeloid chemotaxis to reverse prostate cancer therapy resistance. Guo C, Sharp A, Gurel B, Crespo M, Figueiredo I, Jain S, Vogl U, Rekowski J, Rouhifard M, Gallagher L, Yuan W, Carreira S, Chandran K, Paschalis A, Colombo I, **Stathis A**, Bertan C, Seed G, Goodall J, Raynaud F, Ruddle R, Swales KE, Malia J, Bogdan D, Tiu C, Caldwell R, Aversa C, Ferreira A, Neeb A, Tunariu N, Westaby D, Carmichael J, Fenor de la Maza MD, Yap C, Matthews R, Badham H, Prout T, Turner A, Parmar M, Tovey H, Riisnaes R, Flohr P, Gil J, Waugh D, Decordova S, Schlag A, Calì B, Alimonti A, de Bono JS. Nature. 2023 Nov;623(7989):1053-1061. doi: 10.1038/s41586-023-06696-z. Epub 2023 Oct 16. PMID: 37844613; PMCID: PMC10686834.
14. A Phase I Study of the Pan-Notch Inhibitor CB-103 for Patients with Advanced Adenoid Cystic Carcinoma and Other Tumors. Hanna GJ, **Stathis A**, Lopez-Miranda E, Racca F, Quon D, Leyvraz S, Hess D, Keam B, Rodon J, Ahn MJ, Kim HR, Schneeweiss A, Ribera JM, DeAngelo D, Perez Garcia JM, Cortes J, Schönborn-Kellenberger O, Weber D, Pisa P, Bauer M, Beni L, Bobadilla M, Lehal R, Vigolo M, Vogl FD, Garralda E. Cancer Res Commun. 2023 Sep 14;3(9):1853-1861. doi: 10.1158/2767-9764.CRC-23-0333. PMID: 37712875; PMCID: PMC10501326.
15. Prognostic implication of PD-L1 in early-stage non-small cell lung cancer: a retrospective single-centre study. Cekani E, Martorell C, Martucci F, Patella M, Cafarotti S, Valenti A, Freguia S, Molinari F, Froesch P, Frattini M, **Stathis A**, Wannesson L.
Swiss Med Wkly. 2023 Sep 1;153:40110. doi: 10.57187/smw.2023.40110. PMID: 37769653.
16. Loncastuximab tesirine in relapsed/refractory diffuse large B-cell lymphoma: long-term efficacy and safety from the phase 2 LOTIS-2 study. Caimi PF, Ai WZ, Alderuccio JP, Ardeshna KM, Hamadani M, Hess B, Kahl BS, Radford J, Solh M, **Stathis A**, Zinzani PL, Wang Y, Qin Y, Wang L, Xu ZC, Carlo-Stella C.

Haematologica. 2023 Aug 31. doi: 10.3324/haematol.2023.283459. Epub ahead of print. PMID: 37646659.

17. Results of an open-label phase 1b study of the ERK inhibitor MK-8353 plus the MEK inhibitor selumetinib in patients with advanced or metastatic solid tumors
Stathis A*, Tolcher AW, Wang JS, Renouf DJ, Chen LC, Suttner LH, Freshwater T, Webber AL, Nayak T, Siu LL.
Invest New Drugs. 2023 Jun;41(3):380-390. doi: 10.1007/s10637-022-01326-3. Epub 2023 Apr 11. PMID: 37040046 Free PMC article. Clinical Trial.
18. Safety and anti-tumor activity of lisavanbulin administered as 48-hour infusion in patients with ovarian cancer or recurrent glioblastoma: a phase 2a study.
Joerger M, Hundesberger T, Haefliger S, von Moos R, Hottinger AF, Kaindl T, Engelhardt M, Marszewska M, Lane H, Roth P, **Stathis A**.
Invest New Drugs. 2023 Apr;41(2):267-275. doi: 10.1007/s10637-023-01336-9. Epub 2023 Feb 16. PMID: 36792805 Free PMC article. Clinical Trial.
19. In vitro anti-lymphoma activity of the first-in-class pan-NOTCH transcription inhibitor CB-103.
Spriano F, Tarantelli C, Arribas AJ, Gaudio E, Cascione L, Aresu L, Rinaldi A, Zucca E, Rossi D, **Stathis A**, Murone M, Radtke F, Lehal R, Bertoni F.
Br J Haematol. 2023 Mar;200(5):669-672. doi: 10.1111/bjh.18576. Epub 2022 Dec 9. PMID: 36484636
20. ERBB4-mediated signaling is a mediator of resistance to BTK and PI3K inhibitors in B cell lymphoid neoplasms.
Arribas AJ, Napoli S, Cascione L, Barnabei L, Sartori G, Cannas E, Gaudio E, Tarantelli C, Mensah AA, Spriano F, Zucchetto A, Rossi FM, Rinaldi A, de Moura MC, Jovic S, Pittau RB, **Stathis A**, Stussi G, Gattei V, Brown JR, Esteller M, Zucca E, Rossi D, Bertoni F.
bioRxiv. 2023 Jan 2:2023.01.01.522017. doi: 10.1101/2023.01.01.522017. Preprint. PMID: 36711490 Free PMC article.
21. Phase I study of lurbinectedin in combination with weekly paclitaxel with or without bevacizumab in patients with advanced solid tumors.
Calvo E, Sessa C, Harada G, de Miguel M, Kahatt C, Luepke-Estefan XE, Sigüero M, Fernandez-Teruel C, Cullell-Young M, **Stathis A**, Drilon A.
Invest New Drugs. 2022 Dec;40(6):1263-1273. doi: 10.1007/s10637-022-01281-z. Epub 2022 Aug 10. PMID: 35947247 Free PMC article. Clinical Trial.
22. Resistance to PI3K δ inhibitors in marginal zone lymphoma can be reverted by targeting the IL-6/PDGFRA axis.
Arribas AJ, Napoli S, Cascione L, Sartori G, Barnabei L, Gaudio E, Tarantelli C, Mensah AA, Spriano F, Zucchetto A, Rossi FM, Rinaldi A, Castro de Moura M, Jovic

S, Bordone-Pittau R, Di Veroli A, **Stathis A**, Cruciani G, Stussi G, Gattei V, Brown JR, Esteller M, Zucca E, Rossi D, Bertoni F.
Haematologica. 2022 Nov 1;107(11):2685-2697. doi:
10.3324/haematol.2021.279957. PMID: 35484662 Free PMC article.

23. Loncastuximab tesirine in relapsed/refractory high-grade B-cell lymphoma: a subgroup analysis from the LOTIS-2 study.
Alderuccio JP, Ai WZ, Radford J, Solh M, Ardesbna KM, Lunning MA, Hess BT, Zinzani PL, **Stathis A**, Carlo-Stella C, Hamadani M, Kahl BS, Ungar D, Kilavuz T, Yu E, Qin Y, Caimi PF. Blood Adv. 2022 Aug 23;6(16):4736-4739. doi: 10.1182/bloodadvances.2022007782. PMID: 35790100 Free PMC article.
24. Pharmacologic screen identifies active combinations with BET inhibitors and LRRK2 as a novel putative target in lymphoma.
Spriano F, Sartori G, Tarantelli C, Barreca M, Golino G, Rinaldi A, Napoli S, Mascia M, Scalise L, Arribas AJ, Cascione L, Zucca E, **Stathis A**, Gaudio E, Bertoni F. EJHaem. 2022 Jul 27;3(3):764-774. doi: 10.1002/jha2.535. eCollection 2022 Aug. PMID: 36051080 Free PMC article.
25. Zandelisib with continuous or intermittent dosing as monotherapy or in combination with rituximab in patients with relapsed or refractory B-cell malignancy: a multicentre, first-in-patient, dose-escalation and dose-expansion, phase 1b trial.
Pagel JM, Soumerai JD, Reddy N, Jagadeesh D, **Stathis A**, Asch A, Salman H, Kenkre VP, Iasonos A, Llorin-Sangalang J, Li J, Zelenetz AD. Lancet Oncol. 2022 Aug;23(8):1021-1030. doi: 10.1016/S1470-2045(22)00333-3. Epub 2022 Jul 11. PMID: 35835137 Clinical Trial.
26. SAKK 35/15: a phase 1 trial of obinutuzumab in combination with venetoclax in patients with previously untreated follicular lymphoma.
Stathis A*, Mey UJM, Schär S, Hitz F, Pott C, Mach N, Krasniqi F, Novak U, Schmidt C, Hohloch K, Kienle DL, Hess D, Moccia AA, Unterhalt M, Eckhardt K, Hayoz S, Forestieri G, Rossi D, Dirnhofer S, Ceriani L, Sartori G, Bertoni F, Buske C, Zucca E, Hiddemann W. Blood Adv. 2022 Jul 12;6(13):3911-3920. doi: 10.1182/bloodadvances.2021006520. PMID: 35537101 Free PMC article. Clinical Trial.
27. A phase-II study of atezolizumab in combination with obinutuzumab or rituximab for relapsed or refractory mantle cell or marginal zone lymphoma or Waldenström's macroglobulinemia.
Panayiotidis P, Tumyan G, Thieblemont C, Ptushkin VV, Marin-Niebla A, García-Sanz R, Le Gouill S, **Stathis A**, Bottos A, Hamidi H, Katz P, Perretti T, Willis JC, Buske C.

Leuk Lymphoma. 2022 May;63(5):1058-1069. doi: 10.1080/10428194.2021.2015765. Epub 2022 Jan 19. PMID: 35045765 Clinical Trial.

28. Outcome and Prognostic Factors of COVID-19 Infection in Swiss Cancer Patients: Final Results of SAKK 80/20 (CaSA)
Joerger M, Metaxas Y, Zaman K, Michielin O, Mach N, Bettini A, Schmitt AM, Cantoni N, Caspar CB, Stettler S, Malval R, Pless M, Britschgi C, Renner C, Koeberle D, Schulz JD, Kopp C, Hayoz S, **Stathis A**, von Moos R; Swiss Group for Clinical Cancer Research (SAKK). **Equally contributed** Cancers (Basel). 2022 Apr 27;14(9):2191. doi: 10.3390/cancers14092191. PMID: 35565320 Free PMC article.
29. Genetic and phenotypic attributes of splenic marginal zone lymphoma.
Bonfiglio F, Brusca A, Guidetti F, Terzi di Bergamo L, Faderl M, Spina V, Condoluci A, Bonomini L, Forestieri G, Koch R, Piffaretti D, Pini K, Piroso MC, Cittone MG, Arribas A, Lucioni M, Ghilardi G, Wu W, Arcaini L, Baptista MJ, Bastidas G, Bea S, Boldorini R, Broccoli A, Buehler MM, Canzonieri V, Cascione L, Ceriani L, Cogliatti S, Corradini P, Derenzini E, Devizzi L, Dietrich S, Elia AR, Facchetti F, Gaidano G, Garcia JF, Gerber B, Ghia P, Gomes da Silva M, Gritti G, Guidetti A, Hitz F, Inghirami G, Ladetto M, Lopez-Guillermo A, Lucchini E, Maiorana A, Marasca R, Matutes E, Meignin V, Merli M, Moccia A, Mollejo M, Montalban C, Novak U, Oscier DG, Passamonti F, Piazza F, Pizzolitto S, Rambaldi A, Sabattini E, Salles G, Santambrogio E, Scarfò L, **Stathis A**, Stüssi G, Geyer JT, Tapia G, Tarella C, Thieblemont C, Tousseyn T, Tucci A, Vanini G, Visco C, Vitolo U, Walewska R, Zaja F, Zenz T, Zinzani PL, Khiabani H, Calcinotto A, Bertoni F, Bhagat G, Campo E, De Leval L, Dirnhofer S, Pileri SA, Piris MA, Traverse-Glehen A, Tzankov A, Paulli M, Ponzoni M, Mazzucchelli L, Cavalli F, Zucca E, Rossi D.
Blood. 2022 Feb 3;139(5):732-747. doi: 10.1182/blood.2021012386. PMID: 34653238 Clinical Trial.
30. A phase I trial of lurbinectedin in combination with cisplatin in patients with advanced solid tumors.
Metaxas Y, Kahatt C, Alfaro V, Fudio S, Zeaiter A, Plummer R, Sessa C, Von Moos R, Forster M, **Stathis A**.
Invest New Drugs. 2022 Feb;40(1):91-98. doi: 10.1007/s10637-021-01142-1. Epub 2021 Aug 28. PMID: 34453241 Clinical Trial.
31. A phase I trial of inotuzumab ozogamicin in combination with temsirolimus in patients with relapsed or refractory CD22-positive B-cell non-Hodgkin lymphomas.
Piroso MC, Zhang L, Hitz F, Novak U, Hess D, Terrot T, Pascale M, Mazzucchelli L, Bertoni F, Cavalli F, Zucca E, **Stathis A**.
Leuk Lymphoma. 2022 Jan;63(1):117-123. doi: 10.1080/10428194.2021.1966780. Epub 2021 Aug 19. PMID: 34407735 Clinical Trial.

32. Efficacy and Safety Exposure-Response Analysis of Loncastuximab Tesirine in Patients with B cell non-Hodgkin Lymphoma.
Hess B, Townsend W, Ai W, **Stathis A**, Solh M, Alderuccio JP, Ungar D, Liao S, Liao L, Khouri L, Zhang X, Boni J.
AAPS J. 2021 Dec 10;24(1):11. doi: 10.1208/s12248-021-00660-3. PMID: 34893942
33. A Phase II Study to Assess the Safety and Efficacy of the Dual mTORC1/2 and PI3K Inhibitor Bimiralisib (PQR309) in Relapsed, Refractory Lymphoma.
Collins GP, Eyre TA, Schmitz-Rohmer D, Townsend W, Popat R, Giulino-Roth L, Fields PA, Krasniqi F, Soussain C, **Stathis A**, Andjelkovic N, Cunningham D, Mandic D, Radulovic S, Tijanic I, Horowitz NA, Kurtovic S, Schorb E, Schmidt C, Dimitrijević S, Dreyling M.
Hemasphere. 2021 Oct 27;5(11):e656. doi: 10.1097/HS9.0000000000000656. eCollection 2021 Nov. PMID: 34901759 Free PMC article.
34. Phase I Dose-Escalation Study of the Dual PI3K-mTORC1/2 Inhibitor Gedatolisib in Combination with Paclitaxel and Carboplatin in Patients with Advanced Solid Tumors.
Colombo I, Genta S, Martorana F, Guidi M, Frattini M, Samartzis EP, Brandt S, Gaggetta S, Moser L, Pascale M, Terrot T, Sessa C, **Stathis A**.
Clin Cancer Res. 2021 Sep 15;27(18):5012-5019. doi: 10.1158/1078-0432.CCR-21-1402. Epub 2021 Jul 15. PMID: 34266890 Clinical Trial.
35. Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial.
Caimi PF, Ai W, Alderuccio JP, Ardeschna KM, Hamadani M, Hess B, Kahl BS, Radford J, Solh M, **Stathis A**, Zinzani PL, Havenith K, Feingold J, He S, Qin Y, Ungar D, Zhang X, Carlo-Stella C.
Lancet Oncol. 2021 Jun;22(6):790-800. doi: 10.1016/S1470-2045(21)00139-X. Epub 2021 May 11. PMID: 33989558 Clinical Trial.
36. Do oncologists prefer subspecialty radiology reports? A quality care study.
Rizzo S, Del Grande M, Espeli V, Stathis A, Nicolino GM, Del Grande F.
Insights Imaging. 2021 May 26;12(1):64. doi: 10.1186/s13244-021-01007-4. PMID: 34037872 Free PMC article.
37. Study of the antilymphoma activity of pracinostat reveals different sensitivities of DLBCL cells to HDAC inhibitors.
Mensah AA, Spriano F, Sartori G, Priebe V, Cascione L, Gaudio E, Tarantelli C, Civanelli E, Aresu L, Rinaldi A, Damia G, Lovati E, Zucca E, **Stathis A**, Pietra C, Bertoni F.
Blood Adv. 2021 May 25;5(10):2467-2480. doi: 10.1182/bloodadvances.2020003566. PMID: 33999145 Free PMC article.

38. Adverse Event Reporting with Immune Checkpoint Inhibitors in Older Patients: Age Subgroup Disproportionality Analysis in VigiBase.
Nosedà R, Bonaldo G, Motola D, **Stathis A**, Ceschi A.
Cancers (Basel). 2021 Mar 6;13(5):1131. doi: 10.3390/cancers13051131.
PMID: 33800813 Free PMC article.
39. A phase II trial of bendamustine in combination with ofatumumab in patients with relapsed or refractory marginal zone B-cell lymphomas.
Vannata B, Vanazzi A, Negri M, Liptrott SJ, Bartosek AA, Miani M, Di Sanzo A, Cavalli F, Zucca E, **Stathis A***.
Hematol Oncol. 2021 Feb;39(1):60-65. doi: 10.1002/hon.2822. Epub 2020 Nov 6.
PMID: 33103778 Clinical Trial.
40. The bromodomain and extra-terminal domain degrader MZ1 exhibits preclinical anti-tumoral activity in diffuse large B-cell lymphoma of the activated B cell-like type.
Tarantelli C, Cannas E, Ekeh H, Moscatello C, Gaudio E, Cascione L, Napoli S, Rech C, Testa A, Maniaci C, Rinaldi A, Zucca E, **Stathis A**, Ciulli A, Bertoni F.
Explor Target Antitumor Ther. 2021;2(6):586-601. doi: 10.37349/etat.2021.00065.
Epub 2021 Dec 31. PMID: 36046113 Free PMC article.
41. Targeting CD205 with the antibody drug conjugate MEN1309/OBT076 is an active new therapeutic strategy in lymphoma models.
Gaudio E, Tarantelli C, Spriano F, Guidetti F, Sartori G, Bordone R, Arribas AJ, Cascione L, Bigioni M, Merlino G, Fiascarelli A, Bressan A, Adjeiwaa Mensah A, Golino G, Lucchini R, Bernasconi E, Rossi D, Zucca E, Stussi G, **Stathis A**, Boyd RS, Dusek RL, Bisht A, Attanasio N, Rohlf C, Pellacani A, Binaschi M, Bertoni F.
Haematologica. 2020 Nov 1;105(11):2584-2591. doi: 10.3324/haematol.2019.227215. PMID: 33131247 Free PMC article.
42. Antitumor activity of the dual BET and CBP/EP300 inhibitor NEO2734.
Spriano F, Gaudio E, Cascione L, Tarantelli C, Melle F, Motta G, Priebe V, Rinaldi A, Golino G, Mensah AA, Aresu L, Zucca E, Pileri S, Witcher M, Brown B, Wahlestedt C, Giles F, **Stathis A**, Bertoni F.
Blood Adv. 2020 Sep 8;4(17):4124-4135. doi: 10.1182/bloodadvances.2020001879.
PMID: 32882003 Free PMC article.
43. A Phase 1 study of BAL101553, a novel tumor checkpoint controller targeting microtubules, administered as 48-h infusion in adult patients with advanced solid tumors.
Joerger M, **Stathis A**, Metaxas Y, Hess D, Mantiero M, Mark M, Volden M, Kaindl T, Engelhardt M, Larger P, Lane H, Hafner P, Levy N, Stuedeli S, Sessa C, von Moos R.
Invest New Drugs. 2020 Aug;38(4):1067-1076. doi: 10.1007/s10637-019-00850-z.
Epub 2019 Aug 30. PMID: 31471863 Free PMC article. Clinical Trial.

44. Pembrolizumab in relapsed or refractory Richter syndrome.
Armand P, Murawski N, Molin D, Zain J, Eichhorst B, Gulbas Z, Hawkes EA, Pagel JM, Phillips T, Ribrag V, Svoboda J, **Stathis A**, Chatterjee A, Orlowski R, Marinello P, Christian B.
Br J Haematol. 2020 Jul;190(2):e117-e120. doi: 10.1111/bjh.16762. Epub 2020 Jun 16. PMID: 32544980 Free PMC article. Clinical Trial. No abstract available.
45. SAKK38/07 study: integration of baseline metabolic heterogeneity and metabolic tumor volume in DLBCL prognostic model.
Ceriani L, Gritti G, Cascione L, Piroso MC, Polino A, Ruberto T, **Stathis A**, Bruno A, Moccia AA, Giovanella L, Hayoz S, Schär S, Dirnhofer S, Rambaldi A, Martinelli G, Mamot C, Zucca E.
Blood Adv. 2020 Mar 24;4(6):1082-1092. doi: 10.1182/bloodadvances.2019001201. PMID: 32196557 Free PMC article.
46. Copanlisib synergizes with conventional and targeted agents including venetoclax in B- and T-cell lymphoma models.
Tarantelli C, Lange M, Gaudio E, Cascione L, Spriano F, Kwee I, Arribas AJ, Rinaldi A, Jourdan T, Berthold M, Sturz A, Sperl C, Margheriti F, Scalise L, Gritti G, Rossi D, **Stathis A**, Liu N, Zucca E, Politz O, Bertoni F.
Blood Adv. 2020 Mar 10;4(5):819-829. doi: 10.1182/bloodadvances.2019000844. PMID: 32126142 Free PMC article.
47. Single and combined BTK and PI3K δ inhibition with acalabrutinib and ACP-319 in pre-clinical models of aggressive lymphomas.
Spriano F, Tarantelli C, Gaudio E, Gerlach MM, Priebe V, Cascione L, Bernasconi E, Targa A, Mascia M, Dirnhofer S, **Stathis A**, Zucca E, Bertoni F.
Br J Haematol. 2019 Dec;187(5):595-601. doi: 10.1111/bjh.16118. Epub 2019 Jul 29. PMID: 31355927
48. Late relapse in patients with diffuse large B-cell lymphoma: impact of rituximab on their incidence and outcome.
Vannata B, Conconi A, Winkler J, Cascione L, Margiotta Casaluci G, Nassi L, Moia R, Piroso MC, Moccia AA, **Stathis A**, Rossi D, Gaidano G, Zucca E.
Br J Haematol. 2019 Nov;187(4):478-487. doi: 10.1111/bjh.16106. Epub 2019 Aug 5. PMID: 31385291
49. The ETS Inhibitors YK-4-279 and TK-216 Are Novel Antilymphoma Agents.
Spriano F, Chung EYL, Gaudio E, Tarantelli C, Cascione L, Napoli S, Jessen K, Carrassa L, Priebe V, Sartori G, Graham G, Selvanathan SP, Cavalli A, Rinaldi A, Kwee I, Testoni M, Genini D, Ye BH, Zucca E, **Stathis A**, Lannutti B, Toretsky JA, Bertoni F.
Clin Cancer Res. 2019 Aug 15;25(16):5167-5176. doi: 10.1158/1078-0432.CCR-18-2718. Epub 2019 Jun 10. PMID: 31182435

50. The novel CD19-targeting antibody-drug conjugate huB4-DGN462 shows improved anti-tumor activity compared to SAR3419 in CD19-positive lymphoma and leukemia models.
Hicks SW, Tarantelli C, Wilhem A, Gaudio E, Li M, Arribas AJ, Spriano F, Bordone R, Cascione L, Lai KC, Qiu Q, Tadorelli M, Rossi D, Stussi G, Zucca E, **Stathis A**, Sloss CM, Bertoni F.
Haematologica. 2019 Aug;104(8):1633-1639. doi: 10.3324/haematol.2018.211011. Epub 2019 Feb 7. PMID: 30733273 Free PMC article.
51. The Bruton tyrosine kinase inhibitor zanubrutinib (BGB-3111) demonstrated synergies with other anti-lymphoma targeted agents.
Tarantelli C, Zhang L, Curti E, Gaudio E, Spriano F, Priebe V, Cascione L, Arribas AJ, Zucca E, Rossi D, **Stathis A**, Bertoni F.
Haematologica. 2019 Jul;104(7):e307-e309. doi: 10.3324/haematol.2018.214759. Epub 2019 Jan 24. PMID: 30679329 Free PMC article.
52. In vitro demonstration of synergism with pixantrone combined with targeted agents in lymphomas.
Tarantelli C, Gaudio E, Cascione L, **Stathis A**, Zucca E, Bertoni F.
Br J Haematol. 2019 Jul;186(1):149-152. doi: 10.1111/bjh.15727. Epub 2018 Dec 19. PMID: 30569468
53. The Novel TORC1/2 Kinase Inhibitor PQR620 Has Anti-Tumor Activity in Lymphomas as a Single Agent and in Combination with Venetoclax.
Tarantelli C, Gaudio E, Hillmann P, Spriano F, Sartori G, Aresu L, Cascione L, Rageot D, Kwee I, Beaufils F, Zucca E, **Stathis A**, Wymann MP, Cmiljanovic V, Fabbro D, Bertoni F.
Cancers (Basel). 2019 Jun 4;11(6):775. doi: 10.3390/cancers11060775. PMID: 31167506 Free PMC article.
54. Trabectedin is a novel chemotherapy agent for diffuse large B cell lymphoma.
Spriano F, Chung EY, Panini N, Cascione L, Rinaldi A, Erba E, **Stathis A**, D'Incalci M, Bertoni F, Gatta R.
Br J Haematol. 2019 Mar;184(6):1022-1025. doi: 10.1111/bjh.15212. Epub 2018 Apr 2. PMID: 29611184 Free article.
55. Bromodomain and extra-terminal domain inhibition modulates the expression of pathologically relevant microRNAs in diffuse large B-cell lymphoma.
Mensah AA, Cascione L, Gaudio E, Tarantelli C, Bomben R, Bernasconi E, Zito D, Lampis A, Hahne JC, Rinaldi A, **Stathis A**, Zucca E, Kwee I, Gattei V, Valeri N, Riveiro ME, Bertoni F.
Haematologica. 2018 Dec;103(12):2049-2058. doi: 10.3324/haematol.2018.191684. Epub 2018 Aug 3. PMID: 30076183 Free PMC article.

56. Phase Ib Trial With Birabresib, a Small-Molecule Inhibitor of Bromodomain and Extraterminal Proteins, in Patients With Selected Advanced Solid Tumors.
Lewin J, Soria JC, **Stathis A**, Delord JP, Peters S, Awada A, Aftimos PG, Bekradda M, Rezai K, Zeng Z, Hussain A, Perez S, Siu LL, Massard C.
J Clin Oncol. 2018 Oct 20;36(30):3007-3014. doi: 10.1200/JCO.2018.78.2292. Epub 2018 May 7. PMID: 29733771 Clinical Trial.
57. Safety, tolerability, and preliminary activity of IMG529, a CD37-targeted antibody-drug conjugate, in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: a dose-escalation, phase I study.
Stathis A*, Flinn IW, Madan S, Maddocks K, Freedman A, Weitman S, Zucca E, Munteanu MC, Lia Palomba M.
Invest New Drugs. 2018 Oct;36(5):869-876. doi: 10.1007/s10637-018-0570-4. Epub 2018 Feb 17. PMID: 29453628 Free PMC article. Clinical Trial.
58. BET bromodomain inhibitor birabresib in mantle cell lymphoma: in vivo activity and identification of novel combinations to overcome adaptive resistance.
Tarantelli C, Bernasconi E, Gaudio E, Cascione L, Restelli V, Arribas AJ, Spriano F, Rinaldi A, Mensah AA, Kwee I, Ponzoni M MD, Zucca E, Carrassa L, Riveiro ME, Rezai K, **Stathis A**, Cvitkovic E, Bertoni F.
ESMO Open. 2018 Sep 26;3(6):e000387. doi: 10.1136/esmoopen-2018-000387. eCollection 2018. PMID: 30305939 Free PMC article.
59. Metabolic heterogeneity on baseline 18FDG-PET/CT scan is a predictor of outcome in primary mediastinal B-cell lymphoma.
Ceriani L, Milan L, Martelli M, Ferreri AJM, Cascione L, Zinzani PL, Di Rocco A, Conconi A, **Stathis A**, Cavalli F, Bellei M, Cozens K, Porro E, Giovanella L, Johnson PW, Zucca E.
Blood. 2018 Jul 12;132(2):179-186. doi: 10.1182/blood-2018-01-826958. Epub 2018 May 2. PMID: 29720487
60. Circulating tumor DNA reveals genetics, clonal evolution, and residual disease in classical Hodgkin lymphoma.
Spina V, Bruscazzin A, Cuccaro A, Martini M, Di Trani M, Forestieri G, Manzoni M, Condoluci A, Arribas A, Terzi-Di-Bergamo L, Locatelli SL, Cupelli E, Ceriani L, Moccia AA, **Stathis A**, Nassi L, Deambrogi C, Diop F, Guidetti F, Cocomazzi A, Annunziata S, Rufini V, Giordano A, Neri A, Boldorini R, Gerber B, Bertoni F, Ghielmini M, Stüssi G, Santoro A, Cavalli F, Zucca E, Larocca LM, Gaidano G, Hohaus S, Carlo-Stella C, Rossi D.
Blood. 2018 May 31;131(22):2413-2425. doi: 10.1182/blood-2017-11-812073. Epub 2018 Feb 15. PMID: 29449275

61. Outcome of patients older than 80 years with diffuse large B-cell lymphoma (DLBCL) treated with "standard" immunochemotherapy: A large retrospective study from 4 institutions.
Gobba S, Moccia AA, Gulden-Sala W, Conconi A, Diem S, Cascione L, Iacoboni G, Margiotta-Casaluci G, Aprile von Hohenstaufen K, **Stathis A**, Hitz F, Pinotti G, Gaidano G, Zucca E.
Hematol Oncol. 2018 Feb;36(1):84-92. doi: 10.1002/hon.2447. Epub 2017 Jun 16. PMID: 28621491
62. PQR309 Is a Novel Dual PI3K/mTOR Inhibitor with Preclinical Antitumor Activity in Lymphomas as a Single Agent and in Combination Therapy.
Tarantelli C, Gaudio E, Arribas AJ, Kwee I, Hillmann P, Rinaldi A, Cascione L, Spriano F, Bernasconi E, Guidetti F, Carrassa L, Pittau RB, Beaufils F, Ritschard R, Rageot D, Sele A, Dossena B, Rossi FM, Zucchetto A, Tadorelli M, Gattei V, Rossi D, **Stathis A**, Stussi G, Brogginini M, Wymann MP, Wicki A, Zucca E, Cmiljanovic V, Fabbro D, Bertoni F.
Clin Cancer Res. 2018 Jan 1;24(1):120-129. doi: 10.1158/1078-0432.CCR-17-1041. Epub 2017 Oct 24. PMID: 29066507
63. Phase I trial of the oral smoothened inhibitor sonidegib in combination with paclitaxel in patients with advanced solid tumors.
Stathis A*, Hess D, von Moos R, Homicsko K, Griguolo G, Joerger M, Mark M, Ackermann CJ, Allegrini S, Catapano CV, Xyrafas A, Enoiu M, Berardi S, Gargiulo P, Sessa C; Swiss Group for Clinical Cancer Research (SAKK).
Invest New Drugs. 2017 Dec;35(6):766-772. doi: 10.1007/s10637-017-0454-z. Epub 2017 Mar 20. PMID: 28317088 Clinical Trial.
64. Preclinical evaluation of the BET bromodomain inhibitor BAY 1238097 for the treatment of lymphoma.
Bernasconi E, Gaudio E, Lejeune P, Tarantelli C, Cascione L, Kwee I, Spriano F, Rinaldi A, Mensah AA, Chung E, **Stathis A**, Siegel S, Schmees N, Ocker M, Zucca E, Haendler B, Bertoni F.
Br J Haematol. 2017 Sep;178(6):936-948. doi: 10.1111/bjh.14803. Epub 2017 Jun 27. PMID: 28653353
65. Cancer-specific geriatric assessment and quality of life: important factors in caring for older patients with aggressive B-cell lymphoma.
Ribi K, Rondeau S, Hitz F, Mey U, Enoiu M, Pabst T, **Stathis A**, Fischer N, Clough-Gorr KM.
Support Care Cancer. 2017 Sep;25(9):2833-2842. doi: 10.1007/s00520-017-3698-4. Epub 2017 Apr 13. PMID: 28405846 Clinical Trial.
66. Bromodomain inhibitor OTX015 (MK-8628) combined with targeted agents shows strong in vivo antitumor activity in lymphoma.

Gaudio E, Tarantelli C, Ponzoni M, Odore E, Rezai K, Bernasconi E, Cascione L, Rinaldi A, **Stathis A**, Riveiro E, Cvitkovic E, Zucca E, Bertoni F.
Oncotarget. 2016 Sep 6;7(36):58142-58147. doi: 10.18632/oncotarget.10983.
PMID: 27494885 Free PMC article.

67. Combination of the MEK inhibitor pimasertib with BTK or PI3K-delta inhibitors is active in pre-clinical models of aggressive lymphomas.
Gaudio E, Tarantelli C, Kwee I, Barassi C, Bernasconi E, Rinaldi A, Ponzoni M, Cascione L, Targa A, **Stathis A**, Goodstal S, Zucca E, Bertoni F.
Ann Oncol. 2016 Jun;27(6):1123-1128. doi: 10.1093/annonc/mdw131. Epub 2016 Mar 8. PMID: 26961147
68. Clinical Response of Carcinomas Harboring the BRD4-NUT Oncoprotein to the Targeted Bromodomain Inhibitor OTX015/MK-8628
Stathis A*, Zucca E, Bekradda M, Gomez-Roca C, Delord JP, de La Motte Rouge T, Uro-Coste E, de Braud F, Pelosi G, French CA..
Cancer Discov. 2016 May;6(5):492-500. doi: 10.1158/2159-8290.CD-15-1335. Epub 2016 Mar 14. PMID: 26976114 Free PMC article.
69. Bromodomain inhibitor OTX015 in patients with lymphoma or multiple myeloma: a dose-escalation, open-label, pharmacokinetic, phase 1 study
Amorim S ¶, **Stathis A ¶**, Gleeson M, Iyengar S, Magarotto V, Leleu X, Morschhauser F, Karlin L, Broussais F, Rezai K, Herait P, Kahatt C, Lokiec F, Salles G, Facon T, Palumbo A, Cunningham D, Zucca E, Thieblemont C. (**¶ Equally contributed**)
Lancet Haematol. 2016 Apr;3(4):e196-204. doi: 10.1016/S2352-3026(16)00021-1. Epub 2016 Mar 18. PMID: 27063978 Clinical Trial.
70. Phase I Population Pharmacokinetic Assessment of the Oral Bromodomain Inhibitor OTX015 in Patients with Haematologic Malignancies.
Odore E, Lokiec F, Cvitkovic E, Bekradda M, Herait P, Bourdel F, Kahatt C, Raffoux E, **Stathis A**, Thieblemont C, Quesnel B, Cunningham D, Riveiro ME, Rezai K.
Clin Pharmacokinet. 2016 Mar;55(3):397-405. doi: 10.1007/s40262-015-0327-6. PMID: 26341814 Clinical Trial.
71. Histologic Transformation in Marginal Zone Lymphomas.
Conconi A, Franceschetti S, Aprile von Hohenstaufen K, Margiotta-Casaluci G, **Stathis A**, Moccia AA, Bertoni F, Ramponi A, Mazzucchelli L, Cavalli F, Gaidano G, Zucca E.
Ann Oncol. 2015 Nov;26(11):2329-35. doi: 10.1093/annonc/mdv368. Epub 2015 Sep 23. PMID: 26400898
72. The novel atypical retinoid ST5589 down-regulates Aurora Kinase A and has anti-tumour activity in lymphoma pre-clinical models.

Bernasconi E, Gaudio E, Kwee I, Rinaldi A, Cascione L, Tarantelli C, Mensah AA, **Stathis A**, Zucca E, Vesci L, Giannini G, Bertoni F.
Br J Haematol. 2015 Nov;171(3):378-86. doi: 10.1111/bjh.13595. Epub 2015 Aug 3.
PMID: 26235926

73. Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue of the Salivary Glands: A Multicenter, International Experience of 248 Patients (IELSG 41). Jackson AE, Mian M, Kalpadakis C, Pangalis GA, **Stathis A**, Porro E, Conconi A, Cortelazzo S, Gaidano G, Lopez Guillermo A, Johnson PW, Martelli M, Martinelli G, Thieblemont C, McPhail ED, Copie-Bergman C, Pileri SA, Jack A, Campo E, Mazzucchelli L, Ristow K, Habermann TM, Cavalli F, Nowakowski GS, Zucca E. Oncologist. 2015 Oct;20(10):1149-53. doi: 10.1634/theoncologist.2015-0180. Epub 2015 Aug 12. PMID: 26268740 Free PMC article.
74. Utility of baseline 18FDG-PET/CT functional parameters in defining prognosis of primary mediastinal (thymic) large B-cell lymphoma. Ceriani L, Martelli M, Zinzani PL, Ferreri AJ, Botto B, Stelitano C, Gotti M, Cabras MG, Rigacci L, Gargantini L, Merli F, Pinotti G, Mannina D, Luminari S, **Stathis A**, Russo E, Cavalli F, Giovanella L, Johnson PW, Zucca E. Blood. 2015 Aug 20;126(8):950-6. doi: 10.1182/blood-2014-12-616474. Epub 2015 Jun 18. PMID: 26089397 Clinical Trial.
75. The BET Bromodomain inhibitor OTX015 affects pathogenetic pathways in pre-clinical B-cell tumor models and synergizes with targeted drugs. Boi M, Gaudio E, Bonetti P, Kwee I, Bernasconi E, Tarantelli C, Rinaldi A, Testoni M, Cascione L, Ponzoni M, Mensah AA, **Stathis A**, Stussi G, Riveiro ME, Herait P, Inghirami G, Cvitkovic E, Zucca E, Bertoni F. Clin Cancer Res. 2015 Apr 1;21(7):1628-38. doi: 10.1158/1078-0432.CCR-14-1561. Epub 2015 Jan 26. PMID: 25623213
76. Novel HDAC inhibitors exhibit pre-clinical efficacy in lymphoma models and point to the importance of CDKN1A expression levels in mediating their anti-tumor response. Mensah AA, Kwee I, Gaudio E, Rinaldi A, Ponzoni M, Cascione L, Fossati G, **Stathis A**, Zucca E, Caprini G, Bertoni F. Oncotarget. 2015 Mar 10;6(7):5059-71. doi: 10.18632/oncotarget.3239. PMID: 25671298 Free PMC article.
77. A phase I study of the oral gamma secretase inhibitor R04929097 in combination with Gemcitabine in patients with advanced solid tumors (PHL-078/CTEP 8575). Richter S, Bedard PL, Chen EX, Clarke BA, Tran B, Hotte SJ, **Stathis A**, Hirte HW, Razak AR, Reedijk M, Chen Z, Cohen B, Zhang WJ, Wang L, Ivy SP, Moore MJ, Oza AM, Siu LL, McWhirter E. Invest New Drugs. 2014 Apr;32(2):243-9. doi: 10.1007/s10637-013-9965-4. Epub 2013 May 5. PMID: 23645447 Free PMC article. Clinical Trial.

78. A phase Ib dose escalation study of oral pan-PI3K inhibitor buparlisib (BKM120) in combination with the oral MEK1/2 inhibitor trametinib (GSK1120212) in patients with selected advanced solid tumours.
Bedard PL, Tabernero J, Janku F, Wainberg ZA, Paz-Ares L, Vansteenkiste J, Van Cutsem E, Perez-Garcia J, **Stathis A**, Britten CD, Le NT, Carter K, Demanse D, Csonka D, Peters M, Zube A, Nauwelaerts H, Sessa C.
Clin Cancer Res. 2015 Feb 15;21(4):730-8. doi: 10.1158/1078-0432.CCR-14-1814. Epub 2014 Dec 10. PMID: 25500057 Clinical Trial.
79. Clinical activity of everolimus in relapsed/refractory marginal zone B-cell lymphomas: results of a phase II study of the International Extranodal Lymphoma Study Group.
Conconi A, Raderer M, Franceschetti S, Devizzi L, Ferreri AJ, Magagnoli M, Arcaini L, Zinzani PL, Martinelli G, Vitolo U, Kiesewetter B, Porro E, **Stathis A**, Gaidano G, Cavalli F, Zucca E.
Br J Haematol. 2014 Jul;166(1):69-76. doi: 10.1111/bjh.12845. Epub 2014 Mar 27. PMID: 24673512 Clinical Trial.
80. Risk factors of central nervous system relapse in mantle cell lymphoma.
Conconi A, Franceschetti S, Lobetti-Bodoni C, **Stathis A**, Margiotta-Casaluci G, Ramponi A, Mazzucchelli L, Bertoni F, Ghielmini M, Gaidano G, Cavalli F, Zucca E.
Leuk Lymphoma. 2013 Sep;54(9):1908-14. doi: 10.3109/10428194.2013.767454. Epub 2013 Feb 20. PMID: 23339449
81. Prognostic impact of monocyte count at presentation in mantle cell lymphoma.
Aprile von Hohenstaufen K, Conconi A, de Campos CP, Franceschetti S, Bertoni F, Margiotta Casaluci G, **Stathis A**, Ghielmini M, Stussi G, Cavalli F, Gaidano G, Zucca E.
Br J Haematol. 2013 Aug;162(4):465-73. doi: 10.1111/bjh.12409. Epub 2013 Jun 29. PMID: 23808798
82. In vivo RAF signal transduction as a potential biomarker for sorafenib efficacy in patients with neuroendocrine tumours.
Quintela-Fandino M, Krzyzanowska M, Duncan G, Young A, Moore MJ, Chen EX, **Stathis A**, Colomer R, Petronis J, Grewal M, Webster S, Wang L, Siu LL.
Br J Cancer. 2013 Apr 2;108(6):1298-305. doi: 10.1038/bjc.2013.64. Epub 2013 Feb 14. PMID: 23412107 Free PMC article. Clinical Trial.
83. Incidence, risk factors and outcome of histological transformation in follicular lymphoma.
Conconi A, Ponzio C, Lobetti-Bodoni C, Motta M, Rancoita PM, **Stathis A**, Moccia AA, Mazzucchelli L, Bertoni F, Ghielmini M, Cavalli F, Zucca E.
Br J Haematol. 2012 Apr;157(2):188-96. doi: 10.1111/j.1365-2141.2012.09054.x. Epub 2012 Feb 20. PMID: 22348437

84. Phase I study of decitabine in combination with vorinostat in patients with advanced solid tumors and non-Hodgkin's lymphomas.
Stathis A, Hotte SJ, Chen EX, Hirte HW, Oza AM, Moretto P, Webster S, Laughlin A, Stayner LA, McGill S, Wang L, Zhang WJ, Espinoza-Delgado I, Holleran JL, Egorin MJ, Siu LL.
Clin Cancer Res. 2011 Mar 15;17(6):1582-90. doi: 10.1158/1078-0432.CCR-10-1893. Epub 2011 Jan 28. PMID: 21278245 Clinical Trial.
85. Patterns of survival of follicular lymphomas at a single institution through three decades.
Conconi A, Motta M, Bertoni F, Piona C, **Stathis A**, Wannesson L, Gracia E, Filho VB, Abreu DR, Mian M, Froesch P, Mazzucchelli L, Ghielmini M, Cavalli F, Zucca E. Leuk Lymphoma. 2010 Jun;51(6):1028-34. doi: 10.3109/10428191003743460. PMID: 20536347
86. Long-term outcome following Helicobacter pylori eradication in a retrospective study of 105 patients with localized gastric marginal zone B-cell lymphoma of MALT type.
Stathis A, Chini C, Bertoni F, Proserpio I, Capella C, Mazzucchelli L, Pedrinis E, Cavalli F, Pinotti G and Zucca E.
Ann Oncol. 2009 Jun;20(6):1086-93. doi: 10.1093/annonc/mdn760. Epub 2009 Feb 4. PMID: 19193705

REVIEWS AND EDITORIALS

1. Methodology for the Development of Innovative Cancer Therapies Taskforce. Electronic address: lseymour@ctg.queensu.ca. Testing new anticancer drugs before curative locoregional therapies: MDICT 2024 recommendations. ESMO Open. 2024 Aug;9(8):103649. doi: 10.1016/j.esmoop.2024.103649. Epub 2024 Jul 25. PMID: 39059061; PMCID: PMC11338105.
2. Antibody-drug conjugates combinations in cancer treatment. Pretelli G, Mati K, Motta L, **Stathis A**. Explor Target Antitumor Ther. 2024;5(3):714-741. doi: 10.37349/etat.2024.00243. Epub 2024 Jun 27. PMID: 38966169; PMCID: PMC11222717.
3. Tafasitamab for the treatment of patients with diffuse large B-cell lymphoma. Pirosa MC, **Stathis A**, Zucca E. Hum Vaccin Immunother. 2024 Dec 31;20(1):2309701. doi: 10.1080/21645515.2024.2309701. Epub 2024 Feb 1. PMID: 38299612; PMCID: PMC10841029.
4. How to integrate CD19 specific chimeric antigen receptor T cells with other CD19 targeting agents in diffuse large B-cell lymphoma?

de Ramon Ortiz C, Wang S, **Stathis A**, Bertoni F, Zenz T, Novak U, Simonetta F. Hematol Oncol. 2023 Nov 8. doi: 10.1002/hon.3237. Epub ahead of print. PMID: 37937474.

5. Oncology phase I trial design and conduct: time for a change - MDICT Guidelines 2022.
Araujo D, Greystoke A, Bates S, Bayle A, Calvo E, Castelo-Branco L, de Bono J, Drilon A, Garralda E, Ivy P, Kholmanskikh O, Melero I, Pentheroudakis G, Petrie J, Plummer R, Ponce S, Postel-Vinay S, Siu L, Spreafico A, **Stathis A**, Steeghs N, Yap C, Yap TA, Ratain M, Seymour L.
Ann Oncol. 2023 Jan;34(1):48-60. doi: 10.1016/j.annonc.2022.09.158. Epub 2022 Sep 29. PMID: 36182023 Review.
6. A systematic review of contemporary phase I trials in patients with lymphoma.
Griguolo G, Zorzi MF, Piroso MC, Treglia G, Bertoni F, Kuruvilla J, Zucca E, **Stathis A**.
Crit Rev Oncol Hematol. 2022 Dec;180:103860. doi: 10.1016/j.critrevonc.2022.103860. Epub 2022 Oct 18. PMID: 36265547 Review.
7. Report of the First International Symposium on NUT Carcinoma.
French CA, Cheng ML, Hanna GJ, DuBois SG, Chau NG, Hann CL, Storck S, Salgia R, Trucco M, Tseng J, **Stathis A**, Piekarz R, Lauer UM, Massard C, Bennett K, Coker S, Tontsch-Grunt U, Sos ML, Liao S, Wu CJ, Polyak K, Piha-Paul SA, Shapiro GI.
Clin Cancer Res. 2022 Jun 13;28(12):2493-2505. doi: 10.1158/1078-0432.CCR-22-0591. PMID: 35417004 Free PMC article.
8. Targeting the DNA damage response: PARP inhibitors and new perspectives in the landscape of cancer treatment.
Genta S, Martorana F, **Stathis A**, Colombo I.
Crit Rev Oncol Hematol. 2021 Dec;168:103539. doi: 10.1016/j.critrevonc.2021.103539. Epub 2021 Nov 18. PMID: 34800653 Review.
9. A systematic review of phase II trials exploring anti-PD-1/PD-L1 combinations in patients with solid tumors.
Martorana F, Colombo I, Treglia G, Gillessen S, **Stathis A**.
Cancer Treat Rev. 2021 Dec;101:102300. doi: 10.1016/j.ctrv.2021.102300. Epub 2021 Oct 17. PMID: 34688105
10. Radiomics in cervical and endometrial cancer.
Manganaro L, Nicolino GM, Dolciemi M, Martorana F, **Stathis A**, Colombo I, Rizzo S.
Br J Radiol. 2021 Sep 1;94(1125):20201314. doi: 10.1259/bjr.20201314. Epub 2021 Jul 8. PMID: 34233456 Free PMC article. Review.
11. New drugs and pharmacological interactions in real life.

Stathis A.

Hematol Oncol. 2021 Jun;39 Suppl 1:78-82. doi: 10.1002/hon.2859. PMID: 34105810 Review.

12. Targeting BET bromodomain proteins in cancer: The example of lymphomas.
Spriano F, **Stathis A**, Bertoni F.
Pharmacol Ther. 2020 Nov;215:107631. doi: 10.1016/j.pharmthera.2020.107631.
Epub 2020 Jul 18. PMID: 32693114 Review.
13. An overview on anti-tubulin agents for the treatment of lymphoma patients.
Barreca M, **Stathis A**, Barraja P, Bertoni F.
Pharmacol Ther. 2020 Jul;211:107552. doi: 10.1016/j.pharmthera.2020.107552.
Epub 2020 Apr 17. PMID: 32305312 Review.
14. Is There a Role for Dual PI3K/mTOR Inhibitors for Patients Affected with Lymphoma?
Tarantelli C, Lupia A, **Stathis A**, Bertoni F.
Int J Mol Sci. 2020 Feb 5;21(3):1060. doi: 10.3390/ijms21031060. PMID: 32033478
Free PMC article. Review.
15. Bromodomain and Extra-Terminal domain inhibitors for lymphoid malignancies.
Bertoni F, **Stathis A**.
Curr Opin Hematol. 2019 Jul;26(4):273-280. doi: 10.1097/MOH.0000000000000519.
PMID: 31116107 Review.
16. Use of epirubicin to treat diffuse large B-cell lymphoma.
Stathis A, Zucca E.
Lancet Haematol. 2019 Jun;6(6):e292-e293. doi: 10.1016/S2352-3026(19)30082-1.
PMID: 31126526 No abstract available.
17. Correlation between PSA kinetics and PSMA-PET in prostate cancer restaging: A meta-analysis.
Pereira Mestre R, Treglia G, Ferrari M, Pascale M, Mazzara C, Azinwi NC, Llado' A, **Stathis A**, Giovanella L, Roggero E.
Eur J Clin Invest. 2019 Mar;49(3):e13063. doi: 10.1111/eci.13063. Epub 2019 Jan 11. PMID: 30580449
18. BET and EZH2 Inhibitors: Novel Approaches for Targeting Cancer.
Genta S, Piroso MC, **Stathis A**.
Curr Oncol Rep. 2019 Feb 4;21(2):13. doi: 10.1007/s11912-019-0762-x. PMID: 30715616 Review.
19. Reporting of immune checkpoint inhibitor-associated myocarditis.
Noseda R, Magro L, **Stathis A**, Ceschi A.
Lancet. 2018 Aug 4;392(10145):383-384. doi: 10.1016/S0140-6736(18)31557-5.
PMID: 30102169 No abstract available.

20. Report of the 14th International Conference on Malignant Lymphoma (ICML) Closed Workshop on Future Design of Clinical Trials in Lymphomas.
Stathis A, Iasonos A, Seymour JF, Thieblemont C, Ribrag V, Zucca E, Younes A.
Clin Cancer Res. 2018 Jul 1;24(13):2993-2998. doi: 10.1158/1078-0432.CCR-17-3021. Epub 2018 Mar 13. PMID: 29535129
21. Methodology of clinical trials evaluating the incorporation of new drugs in the first-line treatment of patients with diffuse large B-cell lymphoma (DLBCL): a critical review.
Iacoboni G, Zucca E, Ghielmini M, **Stathis A**.
Ann Oncol. 2018 May 1;29(5):1120-1129. doi: 10.1093/annonc/mdy113. PMID: 29659676
22. BET Proteins as Targets for Anticancer Treatment.
Stathis A, Bertoni F.
Cancer Discov. 2018 Jan;8(1):24-36. doi: 10.1158/2159-8290.CD-17-0605. Epub 2017 Dec 20. PMID: 29263030 Review.
23. Staining the target: CD37 expression in lymphomas.
Bertoni F, **Stathis A**.
Blood. 2016 Dec 29;128(26):3022-3023. doi: 10.1182/blood-2016-11-748137. PMID: 28034866 No abstract available.
24. Designs of preoperative biomarkers trials in oncology: a systematic review of the literature.
Marous M, Bièche I, Paoletti X, Alt M, Razak AR, **Stathis A**, Kamal M, Le Tourneau C.
Ann Oncol. 2015 Dec;26(12):2419-28. doi: 10.1093/annonc/mdv378. Epub 2015 Sep 14. PMID: 26371283 Review.
25. The new therapeutical scenario of Hodgkin lymphoma.
Stathis A, Younes A.
Ann Oncol. 2015 Oct;26(10):2026-33. doi: 10.1093/annonc/mdv256. Epub 2015 Jun 2. PMID: 26037796 Review
26. Management of the marginal zone lymphomas.
Vannata B, **Stathis A**, Zucca E.
Cancer Treat Res. 2015;165:227-49. doi: 10.1007/978-3-319-13150-4_9. PMID: 25655612 Review.
27. The management of nongastric MALT lymphomas.
Zucca E, **Stathis A**, Bertoni F.
Oncology (Williston Park). 2014 Jan;28(1):86-93. PMID: 24683726 Review. No abstract available.

28. New agents for the treatment of lymphoma.
Stathis A, Ghielmini M.
Ann Oncol. 2012 Sep;23 Suppl 10:x92-8. doi: 10.1093/annonc/mds310. PMID: 22988000
29. MALT lymphomas: pathogenesis can drive treatment.
Bertoni F, Coiffier B, Salles G, **Stathis A**, Traverse-Glehen A, Thieblemont C, Zucca E.
Oncology (Williston Park). 2011 Nov 15;25(12):1134-42, 1147. PMID: 22229204
Review.
30. Targeting Wee1-like protein kinase to treat cancer.
Stathis A, Oza A.
Drug News Perspect. 2010 Sep;23(7):425-9. doi: 10.1358/dnp.2010.23.7.1490760. PMID: 20862394 Review.
31. Treatment of gastric marginal zone lymphoma of MALT type.
Stathis A, Bertoni F, Zucca E.
Expert Opin Pharmacother. 2010 Sep;11(13):2141-52. doi: 10.1517/14656566.2010.497141. PMID: 20586708 Review.
32. Choice of starting dose for molecularly targeted agents evaluated in first-in-human phase I cancer clinical trials.
Le Tourneau C, **Stathis A**, Vidal L, Moore MJ, Siu LL.
J Clin Oncol. 2010 Mar 10;28(8):1401-7. doi: 10.1200/JCO.2009.25.9606. Epub 2010 Feb 1. PMID: 20124167 Review.
33. Advanced pancreatic carcinoma: current treatment and future challenges.
Stathis A, Moore MJ.
Nat Rev Clin Oncol. 2010 Mar;7(3):163-72. doi: 10.1038/nrclinonc.2009.236. Epub 2010 Jan 26. PMID: 20101258 Review.
34. Marginal zone lymphomas.
Zucca E, Bertoni F, **Stathis A**, Cavalli F.
Hematol Oncol Clin North Am. 2008 Oct;22(5):883-901, viii. doi: 10.1016/j.hoc.2008.07.011. PMID: 18954742 Review.

CASE REPORTS

1. Uncommon somatic mutations in metastatic NUT midline carcinoma.
Cavalieri S, **Stathis A**, Fabbri A, Sonzogni A, Perrone F, Tamborini E, Pelosi G, de Braud F, Platania M.
Tumori. 2017 Nov 15;103(Suppl. 1):e5-e8. doi: 10.5301/tj.5000685. PMID: 28967088
2. A Rare Case of Classical Hodgkin Lymphoma Diagnosed 10 Years after Liver Transplant.
Zhang L, Pereira Mestre R, Bihl F, Bühler M, Vannata B, **Stathis A**.
Case Rep Oncol. 2017 Oct 17;10(3):923-927. doi: 10.1159/000481452. eCollection 2017 Sep-Dec. PMID: 29279693 Free PMC article.
3. A case of Hodgkin lymphoma in a patient with a history of bone pain and an initial diagnosis of chronic osteomyelitis.
Griguolo G, Mazzucchelli L, Cavalli F, Ceriani L, Zucca E, **Stathis A**.
Tumori. 2015 Jun 25;101(3):e99-e102. doi: 10.5301/tj.5000283. PMID: 25908041
4. An Unusual Case of Plasmablastic Lymphoma Presenting as Paravertebral Mass Evaluated by (18)F-FDG PET/CT.
Treglia G, Paone G, **Stathis A**, Ceriani L, Giovanella L.
Nucl Med Mol Imaging. 2014 Mar;48(1):89-90. doi: 10.1007/s13139-013-0251-3. Epub 2013 Nov 22. PMID: 24900147 Free PMC article.
5. Cytomegalovirus infection of endocrine system in a patient with diffuse large B-cell lymphoma. Report of a case.
Stathis A, La Rosa S, Proserpio I, Micello D, Chini C, Pinotti G.
Tumori. 2009 Jan-Feb;95(1):119-22. doi: 10.1177/030089160909500123. PMID: 19366071
6. Thrombotic thrombocytopenic purpura associated with renal failure after autologous transplantation for multiple myeloma successfully treated with rituximab.
Gallerani E, Lerch E, Romagnani E, **Stathis A**, Giardelli G, Zwhalen H, Marone C, Cavalli F.
Eur J Haematol. 2006 Dec;77(6):527-9. doi: 10.1111/j.1600-0609.2006.00758.x. Epub 2006 Oct 17. PMID: 17042766

Book chapters

1. Vannata B., **Stathis A.**, Zucca E. Management of the Marginal Zone Lymphomas. In: Evens A., Blum K. (eds) Non-Hodgkin Lymphoma. Cancer Treatment and Research, vol 165. Springer, Cham, (2015)
2. **Stathis A.**, Bertoni F, Zucca E, Cavalli F. "*MALT lymphoma: extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue*". In: Non-Hodgkin Lymphomas: Advanced Diagnostics and Personalized Therapies. Future Medicine, London, UK (2013)
3. Moore M.J and **Stathis A.** "*Pancreatic Adenocarcinoma Surveillance Counterpoint: Canada*". In: Patient Surveillance After Cancer Treatment. Current Clinical Oncology. Johnson, F.E.; Maehara, Y.; Browman, G.P.; Margenthaler, J.A.; Audisio, R.A.; Thompson, J.F.; Johnson, D.Y.; Earle, C.C.; Virgo, K.S. (Eds.)149-152, Humana Press (2013)
4. **Stathis A.**, Siu L.L., Le Tourneau C. "*Preclinical Drug Development: Translating Basic Research into Clinical Work*". In: Clinical Pharmacology of Anti-Cancer Agents. Sessa C., Gianni L., Garassino M., van Halteren H. (Eds) 1-8, ESMO Handbook Series (2012)
5. **Stathis A.**, Lobetti C., Catapano C. Epigenetic Therapy: "*DNA Methyltransferase Inhibitors and Histone Deacetylase Inhibitors*". In: Clinical Pharmacology of Anti-Cancer Agents". Sessa C., Gianni L., Garassino M., van Halteren H. (Eds) 1-8, ESMO Handbook Series (2012)



Bellinzona 2 Sep 2024

Prof. Anastasios Stathis MD